Sung Reul Kim1, Yong Soon Shin2, Jeong Hoon Kim3, Minseon Choi4, Sung-Hee Yoo5. 1. College of Nursing, Chonbuk National University, Jeollabuk-do, Korea. 2. College of Nursing, Hanyang University, Seoul, Korea. Electronic address: ysshin2k@hanyang.ac.kr. 3. Department of Neurosurgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 4. Department of Nursing, Asan Medical Center, Seoul, Korea. 5. College of Nursing, Chonnam National University, Gwangju, Korea.
Abstract
OBJECTIVE: Objectives of this study were to identify and compare symptom clusters in patients with meningioma and glioma and to assess and compare predictors of quality of life (QoL) in both patient groups. METHODS: Data were collected using the MD Anderson Symptom Inventory-Brain Tumor Module, Functional Assessment of Cancer Therapy-General, and Karnofsky Performance Sale. Of 158 participating patients, 77 had meningioma, and 81 had glioma. RESULTS: In patients with meningioma, 4 symptom clusters were identified with 55.4% total variance: 1) physical, 2) cognitive, 3) elimination-appearance, and 4) motor-sensory symptoms. In patients with glioma, 4 clusters with 67.3% total variance were identified: 1) treatment-related, 2) cognitive, 3) appearance-elimination, and 4) gastrointestinal symptoms. Predictors of QoL in patients with meningioma were Karnofsky Performance Scale score (β = 0.41, P < 0.001), cognitive symptom cluster (β = -0.36, P < 0.001), and physical symptom cluster (β = -0.32, P = 0.001), whereas treatment-related symptom cluster (β = -0.55, P < 0.001) was identified as a predictor of QoL in patients with glioma. CONCLUSIONS: In this study, the type and composition of symptom clusters differed between patients with meningioma and glioma. Our data also provide evidence that even when participants reported mild symptoms, these clusters could be used to predict QoL in patients with meningioma and glioma.
OBJECTIVE: Objectives of this study were to identify and compare symptom clusters in patients with meningioma and glioma and to assess and compare predictors of quality of life (QoL) in both patient groups. METHODS: Data were collected using the MD Anderson Symptom Inventory-Brain Tumor Module, Functional Assessment of Cancer Therapy-General, and Karnofsky Performance Sale. Of 158 participating patients, 77 had meningioma, and 81 had glioma. RESULTS: In patients with meningioma, 4 symptom clusters were identified with 55.4% total variance: 1) physical, 2) cognitive, 3) elimination-appearance, and 4) motor-sensory symptoms. In patients with glioma, 4 clusters with 67.3% total variance were identified: 1) treatment-related, 2) cognitive, 3) appearance-elimination, and 4) gastrointestinal symptoms. Predictors of QoL in patients with meningioma were Karnofsky Performance Scale score (β = 0.41, P < 0.001), cognitive symptom cluster (β = -0.36, P < 0.001), and physical symptom cluster (β = -0.32, P = 0.001), whereas treatment-related symptom cluster (β = -0.55, P < 0.001) was identified as a predictor of QoL in patients with glioma. CONCLUSIONS: In this study, the type and composition of symptom clusters differed between patients with meningioma and glioma. Our data also provide evidence that even when participants reported mild symptoms, these clusters could be used to predict QoL in patients with meningioma and glioma.
Authors: Marijke B Coomans; Linda Dirven; Neil K Aaronson; Brigitta G Baumert; Martin Van Den Bent; Andrew Bottomley; Alba A Brandes; Olivier Chinot; Corneel Coens; Thierry Gorlia; Ulrich Herrlinger; Florence Keime-Guibert; Annika Malmström; Francesca Martinelli; Roger Stupp; Andrea Talacchi; Michael Weller; Wolfgang Wick; Jaap C Reijneveld; Martin J B Taphoorn Journal: Neuro Oncol Date: 2019-11-04 Impact factor: 12.300